Simultaneous quantification of budesonide and its two metabolites, 6β‐hydroxybudesonide and 16α‐hydroxyprednisolone, in human plasma by liquid chromatography negative electrospray ionization tandem mass spectrometry

Yaning Wang, Yufei Tang, H. Moellmann, Günther Hochhaus

Biomedical Chromatography · 2003 · 24 citations · 4 references

Concepts

Abstract

A sensitive, rapid and selective liquid chromatography negative electrospray ionization tandem mass spectrometry [LC-(-)ESI-MS-MS] method has been developed and validated for the simultaneous quantification of budesonide (BUD) and its major metabolites, 6beta-hydroxybudesonide (OH-BUD) and 16alpha-hydroxyprednisolone (OH-PRED) in human plasma. The method was validated over a linear range from 0.1 to 10 ng/mL for all three analytes using a solid-phase extraction procedure with 9-fluoro-hydrocortisone as the internal standard. The between-day and within-day coefficients of variation for all compounds were < or =20% at the concentrations of lower limit of quantification and < or =15% at other quality control concentrations. The utility of this assay was demonstrated by monitoring BUD, OH-BUD and OH-PRED plasma concentrations in one healthy subject for 24 h following a 3 mg oral dose of budesonide, administered as a pH modified release capsule (Budenofalk) to healthy volunteers.

References

4